Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
Diffusion tensor imaging detects complex muscle structures in 3D

Diffusion tensor imaging detects complex muscle structures in 3D

Two CUMC studies provide new insights into spinal muscular atrophy

Two CUMC studies provide new insights into spinal muscular atrophy

Molecular link between spinal muscular atrophy and amyotrophic lateral sclerosis

Molecular link between spinal muscular atrophy and amyotrophic lateral sclerosis

Quest Diagnostics announces availability of TERC test for cervical cancer

Quest Diagnostics announces availability of TERC test for cervical cancer

Investigators discover biological explanation for why low levels of oxygen advance SMA symptoms

Investigators discover biological explanation for why low levels of oxygen advance SMA symptoms

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

Advanced understanding of neurodegenerative diseases achieved by Trophos

Advanced understanding of neurodegenerative diseases achieved by Trophos

Introducing missing gene could help extend lives of patients with SMA

Introducing missing gene could help extend lives of patients with SMA

Conference highlights utility of zebrafish for human disorder studies

Conference highlights utility of zebrafish for human disorder studies

New understanding of how motor neurons die in spinal muscular atrophy patients

New understanding of how motor neurons die in spinal muscular atrophy patients

Innovative strategy for regenerating skeletal muscle tissue

Innovative strategy for regenerating skeletal muscle tissue

DYNC1H1 genetic mutation contributes to SMA-LED

DYNC1H1 genetic mutation contributes to SMA-LED

New system measures strength of communication between muscle cells and motor neurons

New system measures strength of communication between muscle cells and motor neurons

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Couples with infertility and miscarriages offered detailed embryo screening with 99% accuracy

Couples with infertility and miscarriages offered detailed embryo screening with 99% accuracy

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Abnormally low level of SMN protein linked to movement problems in spinal muscular atrophy

Abnormally low level of SMN protein linked to movement problems in spinal muscular atrophy

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Drug companies forge joint ventures for smart pills

Drug companies forge joint ventures for smart pills

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec 2011 total revenues increase 7% to $5.0 billion